Atorvastatin calcium (cas 134523-03-8) in combination with methylprednisolone for the treatment of multiple sclerosis relapse

Add time:08/04/2019    Source:sciencedirect.com

This study aimed to investigate the efficacy of combined Atorvastatin calcium (cas 134523-03-8) and methylprednisolone for the treatment of multiple sclerosis relapse. Patients with multiple sclerosis (MS) at the relapse phase were randomized to receive either combined treatment of atorvastatin calcium and methylprednisolone (n = 19) or methylprednisolone alone (n = 19). Expanded Disability Status Scale (EDSS) was administered at baseline, 1 week, 2 weeks, 4 weeks, 3 months, and 6 months after treatment initiation. The number and volume of brain lesions were evaluated using magnetic resonance imaging at baseline and 6 months. The levels of IL-13, IL-35, IFN-γ, and IL-10 in the cerebrospinal fluid were examined using the enzyme-linked immunosorbent assay method. There was no significant difference in EDSS scores at 1, 2, and 4 weeks. At 3 and 6 months, the combined treatment group showed significantly lower EDSS scores than the monotherapy group (P < 0.05). The number and volume of brain lesions in the combined treatment group were significantly lower than the monotherapy group at 6 months (P < 0.001). The mean time to relapse was significantly extended in the combined treatment group than the monotherapy group (P < 0.001). At 2 and 4 weeks, the combined treatment group had significantly higher levels of IL-13, IL-35, and IL-10 in the cerebrospinal fluid than the monotherapy group (P < 0.05), but significantly lower level of IFN-γ (P < 0.001). The levels of IL-13 and IL-10 in the combined treatment group were positively correlated with EDSS scores (r = 0.632, P = 0.001; r = 0.731, P = 0.002). Combined treatment with atorvastatin calcium and methylprednisolone can improve the outcomes of MS relapse compared with glucocorticosteroid alone.

We also recommend Trading Suppliers and Manufacturers of Atorvastatin calcium (cas 134523-03-8). Pls Click Website Link as below: cas 134523-03-8 suppliers

Prev:UHPLC-MS/MS method for determination of Atorvastatin calcium (cas 134523-03-8) in human plasma: Application to a pharmacokinetic study based on healthy volunteers with specific genotype
Next:Development and validation of RP-HPLC method for determination of Atorvastatin calcium (cas 134523-03-8) and Nicotinic acid in combined tablet dosage form)